Our sponsors play a vital role in supporting PHAEUROPE & Global’s mission. Their partnership helps us raise awareness, strengthen advocacy, and improve the lives of people living with pulmonary hypertension across Europe.
AllRock Bio’s team is dedicated to advancing impactful therapies for cardiopulmonary diseases.
We at AOP Orphan are European pioneers in the field of rare diseases, researching, developing, producing, and distributing innovative solutions worldwide since 1996.
Cereno Scientific is advancing a differentiated pipeline focused on rare cardiovascular and pulmonary diseases where current treatment options remain limited.
At Ferrer we do not work to maximize the possible economic profitability for our own benefit, we do it to return to society everything in our hands.
GAAPP raises global quality standards for access to treatment, diagnosis, and care. We support member organizations in meeting the unmet needs of their local patient communities.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
We are Inhibikase Therapeutics, a pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension.
We work hard to understand the experiences of those living with serious diseases as we strive to deliver true change.
GAAPP raises global quality standards for access to treatment, diagnosis, and care. We support member organizations in meeting the unmet needs of their local patient communities.
At Liquidia, we are dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like PAH and PH-ILD to help patients breathe easier and live longer.
For 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.
OrphaCare ist ein internationales, aufstrebendes Unternehmen, das einen speziellen Fokus im Bereich „Medical Devices“ (Medizinprodukte) hat.
Pulmovant is developing innovative therapies, beginning with mosliciguat, to transform the treatment paradigm for people suffering from pulmonary diseases.
Enable Inspiration. Transform the Treatment of Rare Disease. Expand the Availability of Transplantable Organs.